Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein
- PMID: 56452
- DOI: 10.1093/jnci/56.4.735
Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein
Abstract
Prior sc immunization of BALB/c mice with 1 mg isolated M component of MOPC-11 mouse myeloma resulted in significant relative immunity to subsequent sc or ip challenge with 10(4) living cells from the same plasmacytoma. However, challenges of 10(5) and 10(6) tumor cells overcame immune status engendered by preimmunization with M component. Despite evidence for the specificity of the immunity induced by one isolated M component as opposed to another, no clear cytotoxic antibody, cell-mediated tumor-cell lysis, or predominance of either humoral or cell-mediated immune mechanisms were demonstrated. These findings were compatible with a relatively slight tumor-specific antigenicity of M components expressed on tumor surfaces, compared with the tumor specificity of other tumor-related, cell-surface antigens.
Similar articles
-
Passive immunity to murine plasmacytoma by rabbit antiidiotypic antibody to myeloma protein.Proc Soc Exp Biol Med. 1976 Jan;151(1):121-5. doi: 10.3181/00379727-151-39157. Proc Soc Exp Biol Med. 1976. PMID: 1250837
-
Myeloma-specific antibodies: studies of their properties and their relationship to tumor immunity.J Immunol. 1977 Jun;118(6):2206-12. J Immunol. 1977. PMID: 864258 No abstract available.
-
Alteration of cell-surface antigenicity of the mouse plasmacytoma. II. Lack of correlation between synthesis of myeloma protein and alteration of surface antigen.J Natl Cancer Inst. 1977 Feb;58(2):229-37. doi: 10.1093/jnci/58.2.229. J Natl Cancer Inst. 1977. PMID: 833874
-
Immunoregulation of murine myeloma cell growth and differentiation: a monoclonal model of B cell differentiation.Immunol Rev. 1979;48:45-80. doi: 10.1111/j.1600-065x.1979.tb00298.x. Immunol Rev. 1979. PMID: 94898 Review. No abstract available.
-
Myeloma proteins that bind Hsp65 (GroEL) are polyreactive and are found in high incidence in pristine induced plasmacytomas.Curr Top Microbiol Immunol. 2000;252:265-71. doi: 10.1007/978-3-642-57284-5_27. Curr Top Microbiol Immunol. 2000. PMID: 11125484 Review.
Cited by
-
Vaccination strategies in follicular lymphoma.Curr Hematol Malig Rep. 2009 Oct;4(4):189-95. doi: 10.1007/s11899-009-0025-2. Curr Hematol Malig Rep. 2009. PMID: 20425407 Review.
-
Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.Br J Haematol. 2008 Jun;142(2):179-91. doi: 10.1111/j.1365-2141.2008.07143.x. Epub 2008 Apr 13. Br J Haematol. 2008. PMID: 18422783 Free PMC article. Review.
-
Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.BMC Cancer. 2018 Feb 13;18(1):187. doi: 10.1186/s12885-018-4094-2. BMC Cancer. 2018. PMID: 29439670 Free PMC article. Clinical Trial.
-
Vaccination strategies for lymphomas.Curr Oncol Rep. 2003 Sep;5(5):380-6. doi: 10.1007/s11912-003-0022-x. Curr Oncol Rep. 2003. PMID: 12895388 Review.
-
An experimental immunocytoma model in /LOU/M/Ws1 X CFY/F1 rats: neoplastic cells as targets of the host's immune apparatus.Immunology. 1984 Jul;52(3):547-54. Immunology. 1984. PMID: 6204932 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources